One slide in. A complete molecular story out.
Two complementary solutions: spatial and molecular omics, combined and powered by AI to read the biology of a tumor and rank the treatments with the best odds of success.
Four layers of evidence, read together.
Spatial multiomics
Lipid signatures, distinct to each tissue type, are read directly on the tissue map to automatically segment the tumor region from the healthy region of the biopsy, before any destructive step.
Proteomics
High-resolution identification and label-free quantification of the proteins that actually drive the disease.
Transcriptomics
Expression signatures compared to the patient's own healthy tissue to expose the deregulated pathways.
AI interpretation
Algorithms turn raw signal into a readable report: biomarkers, tumor profile and ranked therapeutic options.
Built for the clinic. Built for discovery.
For hospitals & clinics
Better stratification and first-line treatment ranking.
Oncologists, clinicians and pathologists use the platform to better stratify patients and rank first-line treatment options.
Physicians get easy access to spatial omics for lipid pre-screening, plus high-resolution proteomics and transcriptomics profiling, from one unique tissue slide per patient.
Biostatistics and AI tools return a full analysis report of the region of interest and of the patient profile: significant biomarkers, tumor profile and more.
For pharma & biotechs
Known and novel biomarkers, without antibody specificity limits.
Rosetta Omics provides additional methods and data to identify biomarkers of clinical interest.
Because the approach sidesteps antibody specificity problems, we identify both known and novel biomarkers.
The result: faster diagnostic validation, new therapeutic strategies and combinations, and better tumor classification.
Four technologies, chained on a single slide.
Scroll down to reveal the story
Mass spectrometry imaging (MSI)
MALDI-MSI performs a fast spatial pre-screening of lipids and proteins directly on a conductive slide, keeping protein integrity intact.
Laser capture microdissection (LMD)
Specific tissue areas, the regions of interest flagged by imaging, are isolated for downstream molecular identification.
LC-MS/MS
Liquid chromatography coupled to tandem mass spectrometry delivers high-resolution peptide identification and label-free quantification.
Artificial intelligence
Biostatistics and AI drive our biomarker discovery pipeline, producing a full analysis report of the tumor tissue, the tumor micro environment and patient profile, with therapeutic options ranked.
From one tissue section to a treatment decision.
Scroll down to reveal the story
Primary solid tumor
One FFPE or flash frozen tissue section from the patient enters the pipeline.
MALDI MSI
Segmentation and ROI
Laser capture microdissection
Multiomics detection
Data analysis and profiling
Multimodal profile
Three parallel outputs
Primary solid tumor
One FFPE or flash frozen tissue section from the patient enters the pipeline.
"Comparing the tumor to the patient's own healthy tissue gives far more predictive insight into treatment response than any external reference, enabling truly personalized cancer care."